SkinBioTherapeutics (LON:SBTX) Trading Up 14.1% – Here’s What Happened

Shares of SkinBioTherapeutics plc (LON:SBTX) rose 14.1% during mid-day trading on Monday . The company traded as high as GBX 11 and last traded at GBX 10.84. 424,315 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 3,278,070 shares. The stock had previously closed at GBX 9.50.

SkinBioTherapeutics Trading Up 14.1%

The company has a market cap of £28.08 million, a price-to-earnings ratio of -67.72 and a beta of 0.11. The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The firm’s fifty day moving average price is GBX 9.93 and its 200-day moving average price is GBX 11.75.

SkinBioTherapeutics (LON:SBTX) last released its quarterly earnings results on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.The firm had revenue of GBX 217 million for the quarter.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.